NASDAQ:CRIS - Curis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.43 +0.06 (+4.38 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$1.37
Today's Range$1.36 - $1.43
52-Week Range$0.60 - $3.80
Volume107,006 shs
Average Volume230,930 shs
Market Capitalization$47.35 million
P/E Ratio-0.79
Dividend YieldN/A
Beta1.99
Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CRIS
CUSIP23126910
Phone617-503-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.90 million
Book Value$0.73 per share

Profitability

Net Income$-53,310,000.00
Net Margins-316.98%

Miscellaneous

Employees55
Market Cap$47.35 million
Next Earnings Date3/28/2019 (Estimated)
OptionableOptionable

Curis (NASDAQ:CRIS) Frequently Asked Questions

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

When did Curis' stock split? How did Curis' stock split work?

Shares of Curis reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) announced its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.41) by $0.15. The biotechnology company earned $2.36 million during the quarter, compared to analyst estimates of $2.41 million. Curis had a negative return on equity of 299.20% and a negative net margin of 316.98%. View Curis' Earnings History.

When is Curis' next earnings date?

Curis is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for Curis.

What price target have analysts set for CRIS?

3 analysts have issued 12 month price objectives for Curis' shares. Their predictions range from $8.00 to $30.00. On average, they expect Curis' share price to reach $19.00 in the next year. This suggests a possible upside of 1,228.7% from the stock's current price. View Analyst Price Targets for Curis.

What is the consensus analysts' recommendation for Curis?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Curis.

Has Curis been receiving favorable news coverage?

Press coverage about CRIS stock has trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Curis earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the near future.

Who are some of Curis' key competitors?

What other stocks do shareholders of Curis own?

Who are Curis' key executives?

Curis' management team includes the folowing people:
  • Mr. James E. Dentzer, Pres, CEO & Director (Age 52)
  • Dr. Robert E. Martell, Head of R&D (Age 56)
  • Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 60)
  • Mr. Bill Steinkrauss, Corp. Controller & Sr. Director of Fin.
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., Consultant (Age 58)

Who are Curis' major shareholders?

Curis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Arnhold LLC (1.49%), BlackRock Inc. (1.28%), Geode Capital Management LLC (0.66%), Geode Capital Management LLC (0.66%), Fosun International Ltd (0.61%) and Millennium Management LLC (0.54%). Company insiders that own Curis stock include Ali PhD Fattaey, James E Dentzer, James R Mcnab, Kenneth I Kaitin, Marc Rubin and Robert Martell. View Institutional Ownership Trends for Curis.

Which major investors are selling Curis stock?

CRIS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Arnhold LLC and Millennium Management LLC. Company insiders that have sold Curis company stock in the last year include James E Dentzer, Kenneth I Kaitin and Robert Martell. View Insider Buying and Selling for Curis.

Which major investors are buying Curis stock?

CRIS stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd, Bank of New York Mellon Corp, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Curis stock in the last two years include Ali PhD Fattaey and Marc Rubin. View Insider Buying and Selling for Curis.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $1.43.

How big of a company is Curis?

Curis has a market capitalization of $47.35 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Curis employs 55 workers across the globe.

What is Curis' official website?

The official website for Curis is http://www.curis.com.

How can I contact Curis?

Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]


MarketBeat Community Rating for Curis (NASDAQ CRIS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  444 (Vote Outperform)
Underperform Votes:  369 (Vote Underperform)
Total Votes:  813
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel